Scientific educational review. Updated 10 November 2026. Clinical treatment must follow patient-specific assessment and locally approved prescribing information.
Overview
Glaucoma is a group of progressive optic neuropathies leading to retinal ganglion-cell loss and visual-field damage. Raised intraocular pressure (IOP) is a modifiable risk factor, but normal-tension glaucoma also occurs. Therapy targets a personalized IOP reduction and preservation of vision; diagnosis and follow-up require optic nerve, field, angle and pressure assessment [1,2].
Aqueous humor and pharmacologic targets
Aqueous humor is produced by ciliary epithelium, flows through the pupil and exits largely via conventional trabecular meshwork/Schlemm canal drainage and uveoscleral pathways. IOP-lowering drugs either reduce secretion or increase outflow; they do not restore lost optic nerve tissue [1].
Drug classes and mechanism
- Prostaglandin F2α analogues/prostamides: latanoprost, travoprost, tafluprost and bimatoprost primarily increase uveoscleral outflow; some also alter trabecular outflow.
- Topical beta blockers: timolol and betaxolol reduce aqueous humor production through ciliary beta-adrenoceptor blockade.
- Alpha-2 agonists: brimonidine reduces aqueous secretion and can increase uveoscleral outflow.
- Carbonic anhydrase inhibitors: dorzolamide/brinzolamide topical or acetazolamide oral/IV decrease bicarbonate-dependent aqueous secretion.
- Cholinergic miotics: pilocarpine contracts ciliary muscle, enhancing conventional outflow; indications are narrower than in the past.
- Rho kinase inhibitors: netarsudil increases trabecular outflow and can lower episcleral venous pressure; it is a small-molecule kinase inhibitor, not a thrombospondin-domain peptide.
- Other: latanoprostene bunod releases both a prostaglandin analogue and an NO-related moiety to influence outflow [1,2].
Initial management and follow-up
The American Academy of Ophthalmology’s 2026 preferred practice guidance supports prostaglandin analogues as frequent initial medical treatment because of efficacy and once-daily dosing. Selective laser trabeculoplasty is also an acceptable initial or adjunct treatment for suitable primary open-angle glaucoma patients; medical drops are not the only first-line option. Treatment choice considers affordability, adherence, ocular surface disease, contraindications and patient preference. Combination drops can lower treatment burden when multiple medicines are needed [2].
Adverse effects and clinically important precautions
Prostaglandin analogues can cause conjunctival redness, iris pigmentation, eyelash growth and periorbital changes; caution is warranted with active uveitis or susceptible eyes. Topical timolol can be systemically absorbed and cause bradycardia, heart block or bronchospasm, even though administered to the eye. Brimonidine may cause somnolence and is unsafe in very young children. Carbonic anhydrase inhibitors may cause taste changes or electrolyte disturbances, especially systemic acetazolamide; netarsudil can cause conjunctival hyperemia and corneal verticillata. Nasolacrimal occlusion can reduce systemic drop absorption [1,2].
Angle closure is different
Acute primary angle-closure glaucoma is an ophthalmic emergency with pain, redness, blurred vision and often headache/nausea; urgent pressure lowering and definitive laser or surgical intervention may be required. Do not treat it as routine open-angle glaucoma by simply adding long-term drops [1].
References
- Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
- American Academy of Ophthalmology. Primary Open-Angle Glaucoma Preferred Practice Pattern. Ophthalmology. 2026. Available from: https://www.aaojournal.org/article/S0161-6420%2825%2900815-2/fulltext
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.